Viviana Galimberti is director of the Unit of Molecular Senology at the European Institute of Oncology, Milan.
She was born in Milan and earned her MD and specialization in surgery from the University of Milan.
Since 1991 she has been Scientific Consultant and Lecturer for the Italian School of Senology, and since 1995 has been a member of the editorial board of the journal Attualità in Senologia. She holds masters degrees in Plastic Senology and in Medical Management, from Milan’s Catholic University, and is a member of the US Society of Surgical Oncology (SSO).
In addition to her clinical and surgical work in breast cancer, Dr Galimberti is an active clinical researcher, having been closely involved in all the major studies in breast cancer studies carried out the European Institute of Oncology, including seminal ones on sentinel node biopsy and intra-operative radiotherapy with electrons (ELIOT).
Dr Galimberti is chair of the international Trial 23-01, promoted by the International Breast Cancer Study Group (IBCSG) — a randomized study on the utility of axillary dissection versus no axillary dissection in breast cancer patients with only micrometastases in the sentinel node.
The initial results of this study (after five years of follow-up) are currently in press with Lancet Oncology. They show that axillary dissection is not necessary in early breast cancer patients with a clinically clear axilla and only micrometastases in the sentinel node.
As director of the Unit of Molecular Senology, Dr Galimberti is also interested in molecular aspects of breast diseases and in particular is involved in the new study: Understanding How Cancer Stem Cells Drive Breast Cancer Growth..” The primary aim of this study is to develop ways of distinguishing breast cancers that will not progress from those that will and allow application of additional treatments only to patients whose disease is likely to progress. There are several approaches mainly based on identifying cancer stem cells (via miRNA profiles and cell surface receptor profiles). The molecular information thus obtained is also likely to drive the discovery of new anti-cancer drugs. The project is being financed by the Italian Five per 1000 program, under the AIRC (Italian Association for Cancer Research) Special Program in Molecular Clinical Oncology.